FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 104 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC EMA Recommends Extension of Therapeutic Indications for Epcoritamab MOST POPULAR A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer May 3, 2024 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 Load more HOT NEWS Excellence in cancer research nursing: Celebrating innovation during tough times Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... Cancer Control in American Indian and Alaska Native Populations: A Conversation... EMA Adopts a Positive Opinion for Biosimilar Denosumab
